## **Dehydropeptides from Orthogonal Ligation of Unprotected Peptides**

## **Zhenwei Miao and James P. Tam\***

*Department of Microbiology and Immunology, Vanderbilt University, A 5119 MCN, Nash*V*ille, Tennessee 37323*

*tamjp@ctr*V*ax.*V*anderbilt.edu*

**Received September 20, 2000**

## **ABSTRACT**



**A facile method has been developed to synthesize linear and cyclic dehydropeptides from unprotected peptide precursors. This method exploits an N-terminal Cys for a Cys**−**thioester ligation to generate an unprotected peptide and as a precursor for conversion to ∆Ala by**

**ORGANIC LETTERS 2000 Vol. 2, No. 23 <sup>3711</sup>**-**<sup>3713</sup>**

*â***-elimination under mild conditions.**

Dehydropeptides containing  $\alpha$ , $\beta$ -dehydroamino acids are found in naturally occurring peptide antibiotics, toxins, and enzymes. $1-4$  Moreover, they are versatile intermediates because the dehydro moieties can be readily transformed into various unusual amino acids such as lanthionine, lysinoalanine, and *â*-heterocyclic alanines through intra- or intermolecular nucleophilic Michael addition.<sup>1,2,5</sup> Direct stepwise synthesis of dehydropeptides, particularly those containing dehydroalanine (∆Ala), is limited by poor coupling yields of the dehydroamino acids, the instability of the N-terminal ∆Ala, and their susceptibility to nucleophiles during synthesis.6,7 Most syntheses of dehydropeptides are based on the *â*-elimination of modified Cys, Ser, or Thr from protected peptides.8,9 In this Letter, we report a facile method for synthesizing linear and cyclic dehydropeptides from unprotected peptide precursors. This method utilizes a Cys-

(1) Sahl, H.-G.; Jack, R. W.; Bierbaum, G. *Eur. J. Biochem.* **1995**, *230*, .827–885<br>C2) Frie

(2) Friedman, M. *Ad*V*. Exp. Med. Biol.* **<sup>1999</sup>**, *<sup>459</sup>*, 145-159.

(3) Schnell, N.; Entian, K.-D.; Schneider, U.; Gotz, F.; Zähner, H.; Kellner, R.; Jung, G. *Nature* **<sup>1988</sup>**, *<sup>333</sup>*, 276-278.

(4) (a) Fulton, N. D.; Bollenbacher, K.; Templeton, G. E. *Phytopathology* **1965**, *55*, 49. (b) Mayer, W. L.; Templeton, G. E.; Sigel, C. W.; Jones, R.; Woohead, S. H.; Sauer, C. *Tetrahedron Lett.* **1971**, *25*, 2357.

(5) (a) Barbaste, M.; Rolland-Fulcrand, V.; Roumestant, M.-L.; Viallefont, P.; Martinez, J. *Tetrahedron Lett.* **<sup>1998</sup>**, *<sup>39</sup>*, 6287-6290. (b) Ferreira, P. M. T.; Maia, H. L. S.; Monteiro, L. S. *Tetrahedron Lett.* **<sup>1999</sup>**, *<sup>40</sup>*, 4099- 4102.

(6) Schmidt, U.; Lieberknecht, A.; Wild, J. *Synthesis* **<sup>1988</sup>**, *<sup>3</sup>*, 159- 172.

(7) Shin, C.-G.; Yonezawa, Y.; Yamada, T.; Yoshimura, Y. *Bull. Chem. Soc. Jpn.* **<sup>1982</sup>**, *<sup>55</sup>*, 2147-<sup>2152</sup>

10.1021/ol006624r CCC: \$19.00 © 2000 American Chemical Society **Published on Web 10/24/2000**

thioester ligation $10,11$  to generate an unprotected peptide with a Cys at the ligation site as a precursor for conversion to ∆Ala by *â*-elimination under mild conditions (Scheme 1).



Our method was tested in the syntheses of both linear and cyclic dehydropeptides. The unprotected peptide segments P1 bearing a C-terminal thioester were directly synthesized from a thiol resin,<sup>12</sup> while segments  $P_2$  carrying an N-terminal Cys were obtained from a benzyl ester resin using Boc/Bzl chemistry. The linear cysteine-containing precursor was obtained through an intermolecular cysteine-thioester ligation of a  $P_1$  segment and a  $P_2$  segment. For cyclic peptides in which  $P_1$  and  $P_2$  are connected as a single peptide segment, the cyclization was effected by intramolecular Cys-thioester ligation. The ligation was generally performed in reducing aqueous conditions buffered at pH 7 to 8 with a low molecular weight thiol such as 2-mercaptoethanesulfonic acid sodium salt as an additive. $10,11,13$  Under these conditions, the ligations proceeded cleanly and quickly in excellent 90- 95% yields with examples consisting of one linear (entry 5, Table 1) and four cyclic peptides ranging from 5 to 14 residues (entries  $1-4$ , Table 1).<sup>14</sup>



Two methods were used to convert the newly formed cysteine residue at the ligation site to a dehydroamino acid (Scheme 2). Both methods involved transforming the thiol functionality into a leaving group followed by a  $\beta$ -elimination. In method A, the cyanation of the thiol group with  $3-5$ 



equiv of 1-cyano-4-dimethylaminopyridium tetrafluoroborate (CDAP) in a 0.1 M acetic acid solution for  $15-20$  min at 0 °C transformeded the thiol into -SCN under acidic conditions.15 The S-cyanated products obtained in >95% yield were stable under conditions for HPLC purification and lyophilization. These products then underwent *â*-elimination to form an  $\alpha$ , $\beta$ -dehydroalanine in 5-10% DIEA/DMF to afford cyclic and linear <sup>∆</sup>Ala-containing peptides in 64- 79% yields based on the unprotected peptide precursors (Table 2). This method could be also used for a dehydro-

**Table 2.** Summary of Conversion of the Cysteine Residue in a Precursor to a Dehydroalanine Residue in a Product

no.	$precurs$ or $a$	product <sup>b</sup>	method	yield $c$ (%)
	c[CAGFY]	c[AAGFY]	в	83
2	c[CSLKLNG]	c[ΔSLKLNG]	А	79
3	c[CKYSSRGISWSYL]	c[∆KYSSRGISWSYL]	А	76
4	c[CKYSSRGICWSYL]	c[∆KYSSRGI∆WSYL]	А	64
5	<b>SLKLNGCNSFRY</b>	<b>SLKLNGANSFRY</b>	А	70
հ	KPVSLSYRACGG <sup>d</sup>	<b>KPVSLSYRAAGG</b>	А	72

*<sup>a</sup>* C, ligation site. *<sup>b</sup>* ∆, dehydroalanine. *<sup>c</sup>* Total yield from precursor to product. *<sup>d</sup>* From solid-phase synthesis.

peptide containing two cysteine residues such as cyclo- [∆KYSSRGI∆WSYL] (entry 4, Table 2). The *â*-elimination reaction was best performed in nonaqueous conditions. The starting materials and the ∆Ala-containing products are susceptible to alkaline aqueous conditions, which lead to intramolecular cleavage of the Xaa-Cys or hydrolysis and aminolysis of the Xaa $-\Delta$ Ala bond.<sup>15,16</sup> A similar approach using a 2,4-dinitrophenyl fluoride derived thiol functionality as a leaving group to convert Cys to ∆Ala would also be suitable.

(8) (a) Fields, J. B.; Noble, R. L. *Int. J. Pept. Protein Res.* **1990**, *35*, <sup>161</sup>-214. (b) Rich, D. H.; Tam, J. P. *J. Org. Chem.* **<sup>1977</sup>**, *<sup>42</sup>*, 3815-3820. (c) Li, K. W.; Wu, J.; Xing, N. W.; Somon, J. A. *J. Am. Chem. Soc.* **1996**, *<sup>118</sup>*, 7237-7238. (d) Goodall, K.; Parsons, A. *Tetrahedron Lett.* **<sup>1995</sup>**, *<sup>36</sup>*, <sup>3259</sup>-3260. (e) Cherney, R. J.; Wang, L. *J. Org. Chem.* **<sup>1996</sup>**, *<sup>61</sup>*, 2544- 2546. (f) Miller, M. J. *J. Org. Chem.* **<sup>1980</sup>**, *<sup>45</sup>*, 3131-3132. (g) Yamada, M.; Miyajima, T.; Horikawa, H. *Tetrahedron Lett.* **<sup>1998</sup>**, *<sup>39</sup>*, 289-292. (h) Sommerfeld, T. L.; Seebach, D. *Hel*V*. Chim. Acta* **<sup>1993</sup>**, *<sup>76</sup>*, 1702.

(9) (a) Burrage, S.; Raynham, T.; Williams, G.; Essex, J. W.; Allen, C.; Cardno, M.; Swali, V.; Bradley, M. Chem. Eur. J. 2000, 6 1455–1466. (b) Cardno, M.; Swali, V.; Bradley, M. *Chem. Eur. J.* **<sup>2000</sup>**, *<sup>6</sup>* <sup>1455</sup>-1466. (b) Burrage, S.; Raynham, T.; Bradley, M. *Tetrahedron Lett.* **<sup>1998</sup>**, *<sup>39</sup>*, 2831- 2834.

(10) Dawson, P. E.; Muir, T. W.; Clark-Lewis, I.; Kent, S. B. H. *Science* **<sup>1994</sup>**, *<sup>226</sup>*, 776-778.

(11) Tam, J. P.; Lu, Y.-A.; Liu, C. F.; Shao, J. *Proc. Natl. Acad. Sci. U.S.A*. **<sup>1995</sup>**, *<sup>92</sup>*, 12485-12489.

(12) Zhang, L.; Tam, J. P. *J. Am. Chem. Soc.* **<sup>1999</sup>**, *<sup>121</sup>*, 3311-3320. (13) Evans, T. C.; Benner, J. Jr.; Xu, M.-Q. *J. Biol. Chem*. **1999**, *274*,

3923–3926.<br>(14) A tyr (14) A typical procedure for the synthesis of linear peptide through Cys-<br>pester ligation was accomplished using equivalent  $P_1$  and  $P_2$  segments thioester ligation was accomplished using equivalent  $P_1$  and  $P_2$  segments (4 *<sup>µ</sup>*mol of each segment) in 1 mL buffers at pH 7.6 containing 6 M Gua' HCl and 10 equiv of 2-mercaptoethanesulfonic acid sodium salt. The ligation was completed in 3 to 20 h at rt and monitored by HPLC. For synthesis of cyclic peptide, the concentration was diluted to 20 times by the buffers.

(15) Wakselman, M.; Guibe´-Jampel, E. *J. Chem. Soc., Chem. Commun.* **<sup>1976</sup>**, 21-22.

(16) (a) Catsimpoolas, N.; Wood, J. L. *J. Biol. Chem.* **<sup>1966</sup>**, *<sup>241</sup>*, 1790- 1796. (b) Degani, Y.; Neumann, H.; Patchonik, A. *Chem. Eur. J.* **2000**, *6* <sup>1455</sup>-1466. (c) Stark, G. R. *Methods Enzymol.* **<sup>1977</sup>**, *<sup>47</sup>*, 129-132.

Method B utilizing sulfoxide for  $\beta$ -elimination has been used to synthesize protected ΔAla-containing peptides.<sup>8b,9</sup> The three-step reaction (iii to v), methylation, oxidation, and  $\beta$ -elimination, was performed in organic solvents or organicaqueous mixtures. The major difference between methods A and B is the alkylation condition, the former is under acidic whereas the later is under basic conditions. This method was employed to synthesize a water-insoluble ∆Ala-containing peptide (entry 1, Table 2). The S-methylation in 30% DMF and 70% aqueous buffers at pH 8 with a 20-fold excess of iodomethane at rt for 2 h gave the S-methylated compound in 95% yield. Oxidation of thioether to sulfoxide with 2 to 3 equiv of sodium periodate was achieved in 98% yield in H<sub>2</sub>O-dioxane (1:1, v/v) for 4 h at 40 °C. The  $\beta$ -elimination of the sulfoxide with 5% DBU in methanol afforded an 87% yield of the desired cyclic ∆Ala-containing pentapeptide, cyclo[∆AGFY]. It should be noted that Met- or N-terminal Ser-containing peptides are susceptible to the periodate

oxidation in method B.<sup>8b,18</sup> All the cyclic and linear dehydropeptides from both methods A and B were confirmed by MALDI-TOF MS, HPLC, and UV spectroscopy.

In conclusion, we have developed a facile method to synthesize linear and cyclic ∆Ala-containing peptides from unprotected peptide precursors by Cys-thioester ligation. This procedure has the advantage of using the thiol side chain of an N-terminal Cys for the dual purposes of ligation and conversion to a ∆Ala moiety. It may be further utilized as a Michael acceptor of thiol nucleophiles to further elaborate the side chain.<sup>9,19</sup>

**Acknowledgment.** This work was in part supported by U.S. Public Health Service grants NIH GM57145, CA36544, and AI46174.

OL006624R

<sup>(17)</sup> Nakagawa, S.; Tamakashi, Y.; Hamana, T.; Kawase, M.; Taketomi, S.; Ishibashi, Y.; Nishimura, O.; Fukuda, T. *J. Am. Chem. Soc.* **1994**, *116*, <sup>5513</sup>-5514.

<sup>(18)</sup> Geoghegan, K. F.; Stroh, J. G. *Bioconjugate Chem.* **<sup>1992</sup>**, *<sup>3</sup>*, 138- 146.

<sup>(19)</sup> Mayer, J. P.; Zhang, J.; Groeger, S.; Liu, C.-F.; Jarosinski, M. A. *J. Pept. Res.* **<sup>1998</sup>**, *<sup>51</sup>*, 432-436.